drugset / Trial / NCT01259765
Llama Antibody, Rotavirus Diarrhoea, Children
Phase 2
Completed
176 enrolled
International Centre for Diarrhoeal Disease Research, Bangladesh
Unilever Nederland Holdings · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The investigators hypothesize that : oral administration of VHH batch 203027 will be * safe and tolerable for healthy Bangladeshi humans of all age groups (Part I) * effective in reducing severity of diarrhoea in children with proven rotavirus infection (Part II). This entry only covers Part II.
Timeline
- Start
- 2006-01
- Primary completion
- 2008-09
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | VHH batch 203027 | Protein / enzyme biologic | 165 mg | Oral |